HOUSTON, June 03, 2026 – Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its proprietary iPSC-derived human forebrain neural progenitor cell injection, hNPC01. The candidate has displayed potential for treating persistent motor dysfunction due to basal ganglia ischemic stroke in phase I clinical study. [Read more…]
FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison
-
Site will serve as company’s new headquarters and expands capacity and capabilities for induced pluripotent stem cell development and manufacturing
-
New facility is part of a $200 million investment by Fujifilm in expanding research product and cell therapy manufacturing capabilities in the U.S. to support the growing global market
Madison, WI, May 19, 2026 – FUJIFILM Cellular Dynamics Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product portfolio. [Read more…]
Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
- Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs
- Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors (FACT-112), as well as recent advances in Factor’s RNA-based cell reprogramming technologies
- Factor to reveal two novel iPSC-derived mesenchymal stem cell (iMSC) programs: Hypoimmune iMSCs for muscular dystrophy and HTRA1-expressing iMSCs for neurodegenerative disorders
How Induced Pluripotent Stem Cells (iPSCs) Are Changing The World As We Know It
Since their introduction in 2006, iPSCs (or induced pluripotent stem cells) have changed the way we research and treat diseases. In large part, this is thanks to bypassing the ethical concerns associated with embryonic stem cells.
So, why exactly is everyone talking about iPSC applications and their uses within medicine?
If you’re interested in the answer, we’ve made this guide to highlight the ways these stem cells are impacting a wide variety of industries. Let’s get started. [Read more…]
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)
SEATTLE, WA and CAMBRIDGE, UK — Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today announced a distribution agreement to support streamlined and efficient R&D and manufacturing of differentiated cells and tissues from iPSC. This collaboration will provide researchers, product manufacturers, and therapeutic developers with a streamlined, high-performance workflow, pre-qualified to deliver reliable differentiation of iPSCs into product cells and tissues. [Read more…]
- 1
- 2
- 3
- …
- 78
- Next Page »